Imatinib Tablets, Veenat 400 mg

 IMATINIB is a medication that belongs to a class of drugs called protein kinase inhibitors. It is used to treat certain types of cancer, including chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GIST), and myelodysplastic/myeloproliferative diseases (MDS/MPD). Veenat 400 mg is a brand name for IMATINIB.



Veenat 400 mg works by blocking the activity of an abnormal protein that causes cancer cells to grow and divide. By blocking this protein, Veenat 400 mg can help slow or stop the growth of cancer cells.

Before taking Veenat 400 mg, it is important to talk to your doctor about any medical conditions you may have, as well as any other medications or supplements you are taking. Your doctor may also need to perform certain tests to make sure that Veenat 400 mg is safe and appropriate for you to take.

When taking Veenat 400 mg, it is important to follow the dosing instructions carefully, as well as any other instructions provided by your doctor or pharmacist. You should also be aware of potential side effects, which may include nausea, vomiting, diarrhea, fatigue, and fluid retention.

If you have any questions or concerns about Veenat 400 mg or any other medication, be sure to talk to your doctor or pharmacist. They can provide you with more information and help you decide whether Veenat 400 mg is the right treatment option for you.

Location: New Delhi, Delhi 110038, India

Comments

Post a Comment

Popular posts from this blog

Treatment for Acute Myeloid Leukemia: IDHIFA (Enasidenib)

Image
  In the world of oncology, breakthroughs in targeted therapies have opened new avenues for the treatment of various types of cancer. One such remarkable advancement is the introduction of IDHIFA (Enasidenib), a medication that has shown great promise in the fight against acute myeloidleukemia (AML) . Understanding IDHIFA and AML:  IDHIFA, known by its generic name Enasidenib, is an oral medication that targets a specific mutation known as isocitrate dehydrogenase 2 (IDH2). Mutations in the IDH2 gene are found in approximately 12-20% of AML patients. These mutations lead to the production of an abnormal form of the IDH2 enzyme, which plays a significant role in the development and progression of AML. Approved Indication: IDHIFA is specifically indicated for the treatment of adult patients with relapsed or refractory AML harboring an IDH2 mutation. It is not intended for use in patients with other types of leukemia or those without the IDH2 mutation. Accessing IDHIFA: Obtaining IDHIFA
Read more

What Patients Should Know about Early Access Programs- AlleviareIndia

Image
  Introduction: In the world of medical research and development, new treatments, drugs, and therapies are constantly being developed to address various health conditions. However, the journey from initial development to final approval by regulatory authorities can be a lengthy process, leaving many patients eagerly awaiting access to potentially life-saving treatments. This is where Early Access Programs (EAPs) come into play. In this article, we will explore what patients should consider when participating in an Early Access Program. Understand the Purpose and Eligibility Criteria: Before considering participation in an Early Access Program, it's important to understand its purpose. EAPs are designed to provide access to investigational treatments for patients who have exhausted all other available options and have a serious or life-threatening condition. Familiarize yourself with the eligibility criteria to determine if you meet the necessary requirements. Discuss with
Read more

Abatacept (Orencia)

Image
Abatacept (Orencia) is often prescribed after failure of an anti-rheumatic agent (DMARD), such as methotrexate. But it can be used as first-line therapy. Ebetasip is used to reduce inflammatory symptoms such as swelling, pain, and stiffness. In the long term, it is expected to prevent joint deformity, therefore helping to maintain range of motion. It is often used in patients with moderate to severe rheumatoid arthritis who have not responded to one or more DMARDs, such as methotrexate, or other biologic drugs. DMARDs are usually tried first. Abatacept may be used alone or in combination with DMARDs, which makes it more potent, but not with other biologic drugs (such as TNF inhibitors). Its use in other diseases is still being studied. Unlike some other biologic drugs, abetacept does not block anti-inflammatory proteins such as TNF-alpha antagonists. Abatacept attaches to the surface of inflammatory cells and blocks communication between these cells. By blocking this communicatio
Read more